ZA200401000B - Adenosine A3 receptor agonists. - Google Patents

Adenosine A3 receptor agonists. Download PDF

Info

Publication number
ZA200401000B
ZA200401000B ZA200401000A ZA200401000A ZA200401000B ZA 200401000 B ZA200401000 B ZA 200401000B ZA 200401000 A ZA200401000 A ZA 200401000A ZA 200401000 A ZA200401000 A ZA 200401000A ZA 200401000 B ZA200401000 B ZA 200401000B
Authority
ZA
South Africa
Prior art keywords
optionally substituted
compound
alkyl
heteroaryl
aryl
Prior art date
Application number
ZA200401000A
Other languages
English (en)
Inventor
Elfatih Elzein
Venkata Palle
Vaibhav Varkhedkar
Jeff Zablocki
Original Assignee
Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutics Inc filed Critical Therapeutics Inc
Publication of ZA200401000B publication Critical patent/ZA200401000B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA200401000A 2001-08-08 2004-02-06 Adenosine A3 receptor agonists. ZA200401000B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31106901P 2001-08-08 2001-08-08

Publications (1)

Publication Number Publication Date
ZA200401000B true ZA200401000B (en) 2004-10-18

Family

ID=23205248

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200401000A ZA200401000B (en) 2001-08-08 2004-02-06 Adenosine A3 receptor agonists.

Country Status (20)

Country Link
US (1) US20030078232A1 (pl)
EP (1) EP1414837B1 (pl)
JP (1) JP4357960B2 (pl)
KR (1) KR100923888B1 (pl)
CN (1) CN1244589C (pl)
AT (1) ATE307136T1 (pl)
AU (1) AU2002327426C1 (pl)
CA (1) CA2456744A1 (pl)
DE (1) DE60206775T2 (pl)
DK (1) DK1414837T3 (pl)
ES (1) ES2247371T3 (pl)
HU (1) HUP0401437A3 (pl)
IL (2) IL160231A0 (pl)
MX (1) MXPA04001185A (pl)
NO (1) NO327997B1 (pl)
NZ (1) NZ530976A (pl)
PL (1) PL368205A1 (pl)
RU (1) RU2298557C2 (pl)
WO (1) WO2003014137A1 (pl)
ZA (1) ZA200401000B (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
EP1434782A2 (en) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US6914053B2 (en) * 2002-09-09 2005-07-05 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
AU2005306325A1 (en) * 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
EP1881991A1 (en) 2005-05-19 2008-01-30 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007047401A2 (en) * 2005-10-13 2007-04-26 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
JP2010522719A (ja) * 2007-03-28 2010-07-08 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
EP2132208A1 (en) 2007-03-28 2009-12-16 NeuroSearch AS Purinyl derivatives and their use as potassium channel modulators
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
JP2011500716A (ja) * 2007-10-16 2011-01-06 ギリアード・パロ・アルト・インコーポレイテッド Ａ３アデノシン受容体アンタゴニスト
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
CA2876780A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
AU2018269403B2 (en) * 2017-05-19 2025-03-27 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
US12310965B2 (en) 2019-03-29 2025-05-27 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
EP3988100A4 (en) * 2019-06-21 2023-07-26 Academy of Military Medical Sciences ADENOSINE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR STEREOISOMERIDE THEREOF AND USE
WO2022143740A1 (zh) * 2020-12-29 2022-07-07 浙江春禾医药科技有限公司 A3腺苷受体激动剂及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists

Also Published As

Publication number Publication date
NO20040969L (no) 2004-04-19
DE60206775D1 (de) 2006-03-02
HUP0401437A3 (en) 2007-05-29
AU2002327426A2 (en) 2003-02-24
JP4357960B2 (ja) 2009-11-04
JP2005501842A (ja) 2005-01-20
ES2247371T3 (es) 2006-03-01
IL160231A0 (en) 2004-07-25
DE60206775T2 (de) 2006-07-20
NZ530976A (en) 2005-07-29
DK1414837T3 (da) 2005-11-07
AU2002327426B2 (en) 2007-06-14
IL160231A (en) 2010-11-30
KR100923888B1 (ko) 2009-10-28
AU2002327426C1 (en) 2008-03-06
RU2004106635A (ru) 2005-07-27
ATE307136T1 (de) 2005-11-15
MXPA04001185A (es) 2005-06-17
US20030078232A1 (en) 2003-04-24
CN1244589C (zh) 2006-03-08
CA2456744A1 (en) 2003-02-20
HUP0401437A2 (hu) 2004-11-29
RU2298557C2 (ru) 2007-05-10
EP1414837A1 (en) 2004-05-06
EP1414837B1 (en) 2005-10-19
CN1538972A (zh) 2004-10-20
WO2003014137A1 (en) 2003-02-20
PL368205A1 (pl) 2005-03-21
NO327997B1 (no) 2009-11-09
KR20040023733A (ko) 2004-03-18

Similar Documents

Publication Publication Date Title
ZA200401000B (en) Adenosine A3 receptor agonists.
AU2002327426A1 (en) Adenosine A3 receptor agonists
CA2451244C (en) Purine derivatives as a2b adenosine receptor antagonists
CA2702644A1 (en) A3 adenosine receptor antagonists
US20040116376A1 (en) Adenosine A3 receptor agonists
WO2003006465A1 (en) Partial and full agonist of a adenosine receptors
AU2004209986B2 (en) Partial and full agonists of A1 adenosine receptors
EP1646390B1 (en) A1 adenosine receptor antagonists
EP1456209B1 (en) A2a adenosine receptor antagonists
EP1537135B1 (en) Adenosine a3 receptor agonists
EP1943251B1 (en) A1 adenosine receptor agonists
HK1093422B (en) A1 adenosine receptor antagonists